ACUTE MYELOID LEUKEMIA

This early-stage study tested the safety of combining three drugs—uproleselan, azacitidine, and venetoclax—for older adults or those too frail for standard intensive chemotherapy who have newly diagnosed acute myeloid leukemia (AML). The goal was to find a safe dose and see if th…

This was an early safety study for a new oral drug called SGR-2921, designed for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to prior treatments. The main goal was to find the highest safe dose and understand how t…

This study tested whether specially prepared immune cells from a stem cell donor could help patients with acute myeloid leukemia (AML) after their transplant. The cells, called MT-401, were given to try to prevent the cancer from coming back or to treat it if it did return. The t…

This early-stage study aimed to find a safe and effective dose of an experimental oral drug called Minnelide for adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatments. The trial involved 27 participants and focused on determining how m…

This early-stage study aimed to test the safety and initial effectiveness of a new drug called SL-172154. It was given alone or combined with standard drugs (azacitidine and/or venetoclax) to adults with higher-risk forms of myelodysplastic syndromes (MDS) or acute myeloid leukem…

This study tested how well two chemotherapy drugs, venetoclax and decitabine, work together to control aggressive blood cancers. It was for older adults newly diagnosed with acute myeloid leukemia (AML) or people whose AML or high-risk myelodysplastic syndrome (MDS) had returned …

This study tested an experimental cell therapy called TCB008 for adults with acute myeloid leukemia (AML) or related conditions where the cancer has returned or not responded to standard treatments. The therapy involves infusing specially grown immune cells from healthy donors to…

This study tested the safety and effectiveness of an experimental drug called MBG453 when combined with two existing drugs (azacitidine and venetoclax) for adults newly diagnosed with acute myeloid leukemia (AML) who were too frail for standard intensive chemotherapy. It aimed to…

This study tested a drug called sabatolimab, alone or with another drug, for people with acute myeloid leukemia (AML). The goal was to see if it could prevent the cancer from coming back in patients who had a small amount of leftover disease after a stem cell transplant. The tria…

This early-stage study tested a new type of treatment called LCAR-AMDR, a CAR-T cell therapy, for adults and teens with acute myeloid leukemia (AML) that has come back or hasn't responded to standard treatments. The main goals were to find a safe dose and see if the therapy could…

This study tested whether adding a new drug called isatuximab to standard chemotherapy could help children whose acute leukemia had come back or not responded to previous treatment. It involved 67 children and young adults, from infants to under 18 years old. The main goal was to…

This study tested whether adding an experimental drug called siremadlin to two standard leukemia drugs could improve treatment responses for adults with acute myeloid leukemia (AML) who are too frail for intensive chemotherapy. It aimed to find a safe dose and see if the three-dr…

This early-stage study tested a new drug called DSP107, given alongside standard cancer drugs, for patients with hard-to-treat forms of leukemia and related blood disorders. The main goals were to find a safe dose and see if the combination could help control the disease. The stu…

This study tested whether combining the drugs venetoclax with azacytidine or DA could prevent relapse in acute myeloid leukemia (AML) patients who still had small amounts of cancer cells after initial treatment. The goal was to see if this 'preemptive' treatment could keep patien…

This early-stage study tested a combination of two drugs, AZD1775 and belinostat, for patients with advanced blood cancers like acute myeloid leukemia (AML) that have returned or not responded to prior treatments. The main goal was to find the safest and most effective dose of th…

This early-stage study tested a new drug, CWP232291, combined with an existing chemotherapy (cytarabine) for adults with acute myeloid leukemia (AML) that had returned or stopped responding to prior treatments. The main goals were to find a safe dose and see if the combination sh…